Plasma biomarkers discriminate clinical forms of multiple sclerosis
| Autor: | Marta Tejera-Alhambra, Armanda Casrouge, Clara de Andrés, Ansgar Seyfferth, Rocío Ramos-Medina, Bárbara Alonso, Janet Vega, Lidia Fernández-Paredes, Matthew L Albert, Silvia Sánchez-Ramón |
|---|---|
| Přispěvatelé: | Department of Immunology, Hospital General Universitario Gregorio Marañón, Département d'Immunologie - Department of Immunology, Institut Pasteur [Paris], Centre d'Immunologie Humaine (CIH), Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), Department of neurology, STAT-UP Statistical Consulting&Services, Center Alicia Koplowitz for Multiple Sclerosis of the Community of Madrid, Department of Clinical Immunology, Hospital Clínico San Carlos, This study was funded by Fundación Mapfre (http://www.fundacionmapfre.org), Fundación Salud 2000 (http://www.fundacionsalud2000.com), Fondo de Investigación Sanitaria (FIS#12/2759), and the European Research Council Starting Award (http://erc.europa.eu). Marta Tejera-Alhambra received an EFIS grant in 2011 for her stay at Institut Pasteur in Paris., Institut Pasteur [Paris] (IP), Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Vougny, Marie-Christine |
| Jazyk: | angličtina |
| Rok vydání: | 2015 |
| Předmět: |
Oncology
Pathology lcsh:Medicine MESH: Chemokine CCL4/blood Logistic regression Cohort Studies MESH: Hepatocyte Growth Factor/blood MESH: Multiple Sclerosis Relapsing-Remitting/blood Chemokine CCL4 lcsh:Science MESH: Cohort Studies Multidisciplinary MESH: Middle Aged Hepatocyte Growth Factor Middle Aged Multiple Sclerosis Chronic Progressive MESH: Case-Control Studies MESH: Predictive Value of Tests 3. Good health MESH: Epidermal Growth Factor/blood Cerebrospinal fluid Predictive value of tests Cytokines [SDV.IMM]Life Sciences [q-bio]/Immunology Female Chemokines Growth factors MESH: Chemokine CCL11/blood Research Article Cohort study Adult Chemokine CCL11 medicine.medical_specialty [SDV.IMM] Life Sciences [q-bio]/Immunology MESH: Biomarkers/blood Diagnosis Differential Multiple sclerosis Multiple Sclerosis Relapsing-Remitting Predictive Value of Tests MESH: Diagnosis Differential Internal medicine medicine MESH: Multiple Sclerosis Chronic Progressive/blood Humans MESH: Multiple Sclerosis Chronic Progressive/diagnosis Inflammation MESH: Humans Receiver operating characteristic Epidermal Growth Factor business.industry lcsh:R Case-control study MESH: Adult MESH: ROC Curve medicine.disease Management of multiple sclerosis MESH: Multiple Sclerosis Relapsing-Remitting/diagnosis ROC Curve Central nervous system Case-Control Studies lcsh:Q Differential diagnosis business MESH: Female Biomarkers |
| Zdroj: | PLoS ONE, Vol 10, Iss 6, p e0128952 (2015) PLoS ONE PLoS ONE, Public Library of Science, 2015, 10 (6), pp.e0128952. ⟨10.1371/journal.pone.0128952⟩ Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid Consejería de Sanidad de la Comunidad de Madrid PLoS ONE, 2015, 10 (6), pp.e0128952. ⟨10.1371/journal.pone.0128952⟩ |
| ISSN: | 1932-6203 |
| DOI: | 10.1371/journal.pone.0128952⟩ |
| Popis: | International audience; Multiple sclerosis, the most common cause of neurological disability in young population after trauma, represents a significant public health burden. Current challenges associated with management of multiple sclerosis (MS) patients stem from the lack of biomarkers that might enable stratification of the different clinical forms of MS and thus prompt treatment for those patients with progressive MS, for whom there is currently no therapy available. In the present work we analyzed a set of thirty different plasma cytokines, chemokines and growth factors present in circulation of 129 MS patients with different clinical forms (relapsing remitting, secondary progressive and primary progressive MS) and 53 healthy controls, across two independent cohorts. The set of plasma analytes was quantified with Luminex xMAP technology and their predictive power regarding clinical outcome was evaluated both individually using ROC curves and in combination using logistic regression analysis. Our results from two independent cohorts of MS patients demonstrate that the divergent clinical and histology-based MS forms are associated with distinct profiles of circulating plasma protein biomarkers, with distinct signatures being composed of chemokines and growth/angiogenic factors. With this work, we propose that an evaluation of a set of 4 circulating biomarkers (HGF, Eotaxin/CCL11, EGF and MIP-1β/CCL4) in MS patients might serve as an effective tool in the diagnosis and more personalized therapeutic targeting of MS patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|